This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Carbidopa and Levodopa

Read time: 1 mins
Marketing start date: 12 Jan 2025
...
 

Summary of product characteristics


Effective Time

20241126

Version

2

Spl Product Data Elements

Carbidopa and Levodopa carbidopa and levodopa CARBIDOPA CARBIDOPA ANHYDROUS LEVODOPA LEVODOPA CROSPOVIDONE (120 .MU.M) FD&C BLUE NO. 2--ALUMINUM LAKE HYDROXYPROPYL CELLULOSE (110000 WAMW) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE MICROCRYSTALLINE CELLULOSE 101 STARCH, CORN light blue round 1721 Carbidopa and Levodopa carbidopa and levodopa CARBIDOPA CARBIDOPA ANHYDROUS LEVODOPA LEVODOPA CROSPOVIDONE (120 .MU.M) FERRIC OXIDE YELLOW HYDROXYPROPYL CELLULOSE (110000 WAMW) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE MICROCRYSTALLINE CELLULOSE 101 STARCH, CORN light yellow round 1722 Carbidopa and Levodopa carbidopa and levodopa CARBIDOPA CARBIDOPA ANHYDROUS LEVODOPA LEVODOPA CROSPOVIDONE (120 .MU.M) FD&C BLUE NO. 2--ALUMINUM LAKE HYDROXYPROPYL CELLULOSE (110000 WAMW) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE MICROCRYSTALLINE CELLULOSE 101 STARCH, CORN light blue round 1723

Application Number

ANDA215999

Brand Name

Carbidopa and Levodopa

Generic Name

carbidopa and levodopa

Product Ndc

70771-1695

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1694-1 Carbidopa and Levodopa Tablets, USP 10 mg/100 mg 100 Tablets Rx only NDC 70771-1695-1 Carbidopa and Levodopa Tablets, USP 25 mg/100 mg 100 Tablets Rx only NDC 70771-1696-1 Carbidopa and Levodopa Tablets, USP 25 mg/250 mg 100 Tablets Rx only 10 mg/100 mg label 25 mg/100 mg label 25 mg/250 mg label

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.